Amplification and Quantification of an Antisense Oligonucleotide from Target microRNA Using Programmable DNA and a Biological Nanopore

Anal Chem. 2017 Feb 21;89(4):2312-2317. doi: 10.1021/acs.analchem.6b03830. Epub 2017 Feb 9.

Abstract

This paper describes a strategy for autonomous diagnoses of cancers using microRNA (miRNA) and therapy for tumor cells by DNA computing techniques and nanopore measurement. Theranostics, which involves the combination of diagnosis and therapy, has emerged as an approach for personalized medicine or point-of-care cancer diagnostics. DNA computing will become a potent tool for theranostics because it functions completely autonomously without the need for external regulations. However, conventional theranostics using DNA computing involves a one-to-one reaction in which a single input molecule generates a single output molecule; the concentration of the antisense drug is insufficient for the therapy in this type of reaction. Herein we developed an amplification system involving an isothermal reaction in which a large amount of the antisense DNA drug was autonomously generated after detecting miRNA from small cell lung cancer. In addition, we successfully quantified the amount of the generated drug molecule by nanopore measurement with high accuracy, which was more accurate than conventional gel electrophoresis. This autonomous amplification strategy is a potent candidate for a broad range of theranostics using DNA computing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Electrochemical Techniques
  • Humans
  • MicroRNAs / analysis*
  • MicroRNAs / metabolism
  • Nanopores*
  • Nucleic Acid Amplification Techniques / methods*
  • Oligonucleotides, Antisense / metabolism*
  • Point-of-Care Systems
  • Precision Medicine

Substances

  • MicroRNAs
  • Oligonucleotides, Antisense